Protective role of *Emblica officinalis* hydro-ethanolic leaf extract in cisplatin induced nephrotoxicity in Rats

Rupal Purena\(^a\), Rohit Seth\(^b\), Renu Bhatt\(^b,\ast\)

\(^a\) Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, 495009, Chhattisgarh, India
\(^b\) Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, 495009, Chhattisgarh, India

**A R T I C L E   I N F O**

Keywords: *Emblica officinalis*  
Cisplatin  
Nephrotoxicity  
Oxidative stress  
Rats

**A B S T R A C T**

Nephrotoxicity is a major limiting factor in cisplatin treatment. In the present study hydro-ethanolic leaf extract of *Emblica officinalis* was investigated for its protective role in cisplatin induced nephrotoxicity. The experiment was designed for 14 days and male Wistar rats were divided into 9 groups (n = 5). Group 1 served as control (with no treatment), group 2 served as a vehicle control and received 0.9% NaCl intraperitoneally (i.p.) on 11th day of the treatment, group 3 received a single dose of cisplatin on 11th day (12 mg/kg body weight, i.p.), group 4–6 received leaf extract only (100 mg/kg, 200 mg/kg and 400 mg/kg body weight, respectively) throughout the treatment, group 7–9 received leaf extract (100 mg/kg, 200 mg/kg and 400 mg/kg body weight, respectively) throughout the treatment and single dose of cisplatin on the 11th day of the leaf extract treatment. At the end of the experiment (i.e. on 14th day) blood samples were collected from all the groups and were sacrificed to study renal functional parameters. Treatment with above doses of *E. officinalis* leaf extract significantly (p ≤ 0.05) attenuates renal damage by decreasing serum creatinine and blood urea nitrogen (BUN), enhanced the activities of Catalase, SOD, GPx, GR and decreased the renal MDA level compared with the cisplatin treatment group. Furthermore the oral administration of Amla leaf extract improves histological damage and morphological changes in RBCs. Our results suggest that, leaf extract of *E. officinalis* may ameliorate renal damage caused by cisplatin.

1. Introduction

Cisplatin (Cis-diaminedichloro platinum II) also called as “The Penicillin of cancer” was the first big chemotherapy drug [1]. FDA in 1978, approved cisplatin as leading anti-cancer drug for several types of cancer, such as bladder cancer, cervical cancer, ovarian cancer, testicular cancer, non-small cell lung cancer, squamous cell carcinoma of the head & neck, with 90% cure rates in testicular cancer, either used alone or combined with other drugs. Even with the advancement of new therapies in the past decades, the use of cisplatin remains strong [2–4]. Although the profound effects of cisplatin in different types of the cancer, the patients experience severe side effects such as vomiting and nausea, myelosuppression, neurotoxicity, ototoxicity and nephrotoxicity that limit its use [5]. Nephrotoxicity is the major limitation in cisplatin treatment as kidney is exposed to large amounts of parent and active metabolites of drugs. The toxic effects of cisplatin in kidney affects approximately 25–35% of patients treated with a single dose, thereby limiting its use in higher doses and compromising its chemotherapeutic efficacy [4]. In kidney the proximal tubules especially S3 segment is severely affected by the cisplatin treatment and is characterized by the loss of microvilli, cellular swelling and condensation of nuclear chromatin. Other functional characters of renal dysfunction are decrease in glomerular filtration, increased serum creatinine and BUN levels, increased lipid peroxidation, and decrease in enzymatic and non-enzymatic antioxidants [2,4,6].

Cisplatin causes tubular cell death by either necrosis or apoptosis depending upon the concentration and duration of exposure of drug. Many of the pathways involved in tumor cell death involve mitochondrial dysfunction and oxidative stress. Many studies have focused on the use of natural and synthetic antioxidants or ROS scavengers for Reno-protection [7]. *In vitro* and *in vivo* studies have reported protective effect of several natural and synthetic antioxidants in cisplatin induced nephrotoxicity.
nephrotoxicity \cite{8-10}. However, lack of data regarding their effects on the antitumor activity of cisplatin and lack of clinical trials limits the clinical application of compounds \cite{4,11,12}.

*E. officinalis* commonly called as Amla (Indian gooseberry) is one of the most studied plant. Plant parts of *E. officinalis* show antibacterial, antioxidant, anti-diabetic, hypolipidemic, anticancer, hepatoprotective, gastroprotective, antilucrenergic, nephroprotective and chemopreventive properties \cite{13,14}. Most important part of plant is fruit and has been explored more for its medicinal values. However, the leaves are explored substantially less. The active constituents of leaves include Apigenin-7-O-(6-butyryl- \(-\)-glucopyranoside), flavanone glycosides, gallic acid, methyl gallate, luteolin-4-O-neohesperidoside, 1,2,3,4,6-penta-O-galloylglucose, trihydroxyisotesterol, 5 \(_6\) \(_6\) \(_7\) \(_7\) -acetoxysitosterol, 5-hydroxymethylfurfural, 2-acetyl-5-methyl furan, pyrogallol, ellagic acid \cite{15-18}. The active constituents of leaves of *E. officinalis* show antibacterial and antioxidant properties \cite{19}, anti-inflammatory properties \cite{20,21}. Huang and Zhong \cite{22} studied the antitumor activity of cisplatin and lack of clinical trials limits the most studied plant. Plant parts of *E. officinalis* show antibacterial, antioxidant, anti-diabetic, hypolipidemic, anticancer, hepatoprotective, gastroprotective, antilucrenergic, nephroprotective and chemopreventive properties \cite{13,14}. Most important part of plant is fruit and has been explored more for its medicinal values. However, the leaves are explored substantially less. The active constituents of leaves include Apigenin-7-O-(6-butyryl- \(-\)-glucopyranoside), flavanone glycosides, gallic acid, methyl gallate, luteolin-4-O-neohesperidoside, 1,2,3,4,6-penta-O-galloylglucose, trihydroxyisotesterol, 5 \(_6\) \(_6\) \(_7\) \(_7\) -acetoxysitosterol, 5-hydroxymethylfurfural, 2-acetyl-5-methyl furan, pyrogallol, ellagic acid [15–18]. The active constituents of leaves of *E. officinalis* show antibacterial and antioxidant properties [19], anti-inflammatory properties [20,21]. Huang and Zhong [22] studied the antitumor mechanism of gallic acid isolated from *Phyllanthus emblica* against hepatocellular carcinoma cells. Nain et al. [23] reported anti-diabetic and antioxidant properties of leaves against streptozotocin-induced type-2 diabetes mellitus (T2DM) rats by enhancing the activities of antioxidant enzymes Recently, Malik et al. [24] reported *E. officinalis* dried fruit extract ameliorates cisplatin induced renal damage through suppression of MAPK induced inflammation and apoptosis.

Based on the pharmacological and ethno botanical reports of *E. officinalis*, the present investigation was focused on studying anti-oxidant properties of plant and protective role of its hydro-ethanolic leaf extract in cisplatin induced nephrotoxicity. We measured enzymatic activities such as SOD, CAT, GPx, GR, along with the hematological and histopathological parameters.

### 2. Materials and method

#### 2.1. Chemicals

Cisplatin was purchased from Thermo Fisher, Waltham, USA. Sulphanilamide, EDTA (Ethylenediamine- tetra acetic acid disodium salt dihydrate), NBT (Nitroblue tetrazolium chloride), Methionine, Riboflavin were procured from Himedia, Mumbai, India. Creatinine assay kit (Erba) was purchased from Transasia Bio-medicals Ltd., Solan, H.P. India, and Urea assay Kit (Auto span) was purchased from Arkray healthcare Pvt. Ltd., Gujrat, India. Hydrogen peroxide was obtained from Fisher Scientific Mumbai, India. All other chemicals were of analytical grade and were purchased from local vendors supplying scientific grade chemicals.

#### 2.2. Preparation of leaf extract

The leaves of *Emblica officinalis* (Amla) were collected from areas near Bilaspur district. The leaves were identified and authenticated by qualified taxonomist from Guru Ghaisidas University, Bilaspur, C.G. The collected leaves were washed with tap water to remove dirt and air dried at room temperature for 7 days. The dried leaves were ground into powder form; 30 g of grounded leaves was extracted by 70% ethanolic solvent using soxhlet extractor for 6–8 h at 70 °C. After the extraction, the extracts were concentrated by evaporating the solvent until it got reduced to a solid mass.

#### 2.3. Animals

Male Wistar rats weighing between 120 to 180gm were used in the experiment. Animals were maintained under controlled environment. Five animals per cage were placed at a temperature of 22 ± 2 °C with 12 h light and 12 h dark cycle. Rats were kept on bed of rice husk and fed on standard rodent diet and water *ad libitum*.

All animal experiments were performed subsequent to the approval of institutional animal ethical committee and by animal regulatory body of the government (Regd. No. 1321/PO/ReBi/10/CPCSEA).

### 2.4. Experimental design

Male Wistar rats were divided into nine groups each containing five rats. Total duration of experiment was 14 days. Group 1 served as control (with no treatment), group 2 served as vehicle control and given vehicle only (0.9% saline) on 11th day of the treatment, group 3 received a single dose of cisplatin (12 mg/kg body weight) in 0.9% saline on 11th day, groups 4–6 were orally administered hydroethanolic extract of *Emblica officinalis* leaves (100 mg/kg, 200 mg/kg and 400 mg/kg body weight, respectively) during entire treatment period, groups 7–9 received hydroethanolic extract of *Emblica officinalis* leaves (100 mg/kg, 200 mg/kg and 400 mg/kg body weight, respectively) during entire treatment period and along with a single dose of cisplatin (12 mg/kg body weight) in 0.9% saline on 11th day.

Cisplatin was prepared in normal saline (0.9% NaCl) and administered intraperitoneally (i.p). Plant extracts were administered via oral gavage and prepared in normal water. Dose of Amla leave extract was selected on the basis of acute toxicity study in its leaves extract \cite{23}. At the end of the experiment (i.e. 14th day of experiment) blood samples were collected for hematological study followed by sacrificing the animal. Kidneys were dissected bilaterally one part of the kidney was fixed in Bouin’s fixative for histopathological study and the other part was kept frozen in −80 °C for enzymatic and biochemical assays.

#### 2.5. Collection of blood and isolation of serum

Blood was collected from animals by puncturing retro-orbital venous sinus and allowed to clot at 37 °C for 40 min and centrifuged at 3000 rpm for 20 min. The serum samples was taken in a clean mini centrifuge tubes and kept refrigerated until further used.

#### 2.6. Preparation of tissue homogenate

72 h after cisplatin treatment all rats were weighed and sacrificed for isolation of kidney. After isolation, kidney samples were immediately weighed and frozen in dry ice and stored at −80 °C until further analysis. Kidney to body weight ratio was calculated. All the enzyme assays were performed on next day of kidney isolation. The Kidney were minced into small pieces and homogenized in ice cold phosphate buffer saline (0.05 M, pH 7.0) to obtain a 10% homogenate. The homogenate was centrifuged at 17000g for 60 min at 4 °C and the supernatant was used for assay of protein, Catalase, SOD, GPx, GR and MDA level.

#### 2.7. Assessment of nephroprotective activity

##### 2.7.1. Hematological analysis

The Renal function test was determined by assaying blood urea nitrogen (BUN) and serum creatinine, BUN and creatinine concentration were measured by Urea assay Kit and Creatinine assay kit respectively.

##### 2.7.2. Estimation of free radical scavenging enzyme

The activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) and glutathione reductase (GR) in kidney tissue were assayed according to the methods reported by various groups (Masayasu and Hiroshi \cite{25}, Paglia and Valentine \cite{26}, Cohen et al. \cite{27} and Carlberg and Mannervik \cite{28} respectively).

##### 2.7.3. Estimation of lipid per-oxidation (LPO)

The concentration of MDA (Malondialdehyde) in kidney tissue as an index of lipid peroxidation was determined by method of Ohkawa et al. \cite{29} using extinction coefficient of 1.56 × 10^5 M \(^{-1}\) cm \(^{-1}\) and expressed as n moles of MDA/g of tissue.
2.8. Estimation of total protein

Total protein content in tissue was determined by the method of Lowry et al. [30] using bovine serum albumin (BSA) as standard.

2.9. Histological analysis

For histological assessment kidney from all the groups were fixed in Bouin’s fixative for 2 days, dehydrated in graded alcohol, cleared in xylene and embedded in paraffin wax. Fine sections (4–5 μm) were cut using a microtome (Leica RM 2125 RTS), mounted on glass slides and stained with eosin- hematoxylin and examined under light microscope for histological damage at 10× magnification, image was taken with a digital camera (Leica DM IL LED) attached to the microscope. Scale bars are equivalent of 50 μm.

2.10. Study of blood cell morphology

The effect of Cisplatin on the blood cell morphology was studied by simple staining of blood smear with gram stain. Blood smear was prepared by placing a single drop of blood on glass slide at a distance of 2 cm from one end and carefully extended to form a uniform smear. The smear was air dried and fixed in 95% ethanol for 10 min. Staining was done using freshly prepared mixture of Giemsa stain (HiMedia lab, Mumbai, India) (0.5 ml of commercial liquid stain diluted in 9.5 ml distilled water) for 30 min. The slides were carefully washed with distilled water, air dried and examined under light microscope equipped with a digital camera (Leica DM IL LED).

2.11. Statistical analysis

All the data was analyzed by one- way analysis of variance (ANOVA) using Minitab 17 software. Values P ≤ 0.05 were considered as statistically significant. Values are represented as Mean ± SEM, for four rats in each group.

3. Results

3.1. Effect of cisplatin and leaf extract on body weight and kidney to body weight ratio

A significant decrease (p ≤ 0.01) in body weight and a significant increase (p ≤ 0.05) in kidney/body weight ratio was observed in cisplatin treated group when compared to normal control group (Table 1). Groups administered various doses of E. officinalis hydro-ethanolic leaf extract along with cisplatin showed there is no significant increase in body weight and corresponding decrease (p > 0.05) in kidney/body weight ratio with dose 400 mg/kg body wt. However, a significant change (p ≤ 0.05) in above parameters was observed in the group treated with 100 mg/kg and 200 mg/kg leaf extract when compared to cisplatin alone treated group. Also, there are no significant changes in body weight and kidney/body wt ratio of groups that received only leaf extract and vehicle control compared to normal control. Our observation suggest that animals receiving cisplatin alone registered a significant decrease in body weight and an increase in kidney/body wt. ratio which was prevented in animals receiving cisplatin along with Amla leaf extract.

3.2. Effect of cisplatin and leaf extract on serum creatinine and blood urea nitrogen

There was no significant changes in both serum creatinine and BUN in vehicle control and groups treated with varying doses of leaf extract, however, both parameters was significantly (p ≤ 0.05) increased in cisplatin treated groups when compared to normal control group (Table 2; Fig. 1). Treatment with leaf extract at 100 mg/kg, 200 mg/kg and 400 mg/kg bodyweight significantly (p ≤ 0.05) prevented the renal dysfunctions, which is reflected by normal serum creatinine and BUN values when compared to cisplatin treated group.

3.3. Effect of cisplatin and leaf extract on markers of oxidative stress

The renal toxicity of cisplatin is mainly associated with induction of oxidative stress, for this reason various enzymatic and non-enzymatic antioxidant markers were measured. As shown in Table 3; Fig. 2 cisplatin treatment significantly decrease (p ≤ 0.01) the activities of various antioxidant enzymes (i.e. CAT, SOD, GPx and GR) and enhanced the renal MDA level (Table 4; Fig. 3; p ≤ 0.01) as compared to normal control group. The effect of various doses of leaf extract (100 mg/kg, 200 mg/kg and 400 mg/kg body weight) on the above markers of oxidative stress was as follows:

### Table 2

**Effect of E. officinalis leaf extract in cisplatin induced renal Creatinine and Blood Urea Nitrogen (BUN) level in normal, leaf extract and Cisplatin treated rats.**

| Groups               | Creatinine (mg/dl) | BUN (mg/dl) |
|----------------------|--------------------|-------------|
| Normal Control       | 0.77 ± 0.06        | 20.29 ± 0.98|
| Vehicle Control      | 0.82 ± 0.04**      | 15.74 ± 0.06** |
| Cisplatin            | 1.65 ± 0.14*       | 49.04 ± 3.61* |
| AET 100 mg/kg        | 0.6 ± 0.07**       | 17.60 ± 0.51** |
| AET 200 mg/kg        | 0.82 ± 0.04**      | 16.86 ± 0.18** |
| AET 400 mg/kg        | 0.72 ± 0.07**      | 14.87 ± 0.61** |
| AET 100 + Cis        | 0.71 ± 0.01*       | 25.09 ± 0.98  |
| AET 200 + Cis        | 0.63 ± 0.22*       | 24.37 ± 1.14* |
| AET 400 + Cis        | 0.79 ± 0.01*       | 22.14 ± 1.43* |

Values are expressed as mean ± SEM, n = 4. "P vs normal control, *P ≤ 0.05 vs normal control, **P ≤ 0.05 vs cisplatin, ns = non-significant vs normal control, NS = non significant vs cisplatin. AET = Amla ethanolic extract, Cis = Cisplatin.

### Table 1

**Effect of E. officinalis leaf extract on body weight, kidney to body weight ratio in normal, leaf extract and Cisplatin treated rats.**

| Groups                  | % Change in body weight (g) | Kidney/body weight ratio × 1000 |
|-------------------------|----------------------------|---------------------------------|
| Normal Control          | +9.22 ± 0.32               | 9.28 ± 0.30                     |
| Vehicle Control         | +6.08 ± 1.50**             | 9.44 ± 0.13**                   |
| Cisplatin               | −3.59 ± 0.19**             | 11.37 ± 0.02*                   |
| AET 100 mg/kg           | +6.89 ± 0.90**             | 6.97 ± 0.02*                    |
| AET 200 mg/kg           | +7.16 ± 1.69**             | 7.45 ± 0.36*                    |
| AET 400 mg/kg           | +9.71 ± 1.68**             | 7.75 ± 0.11**                   |
| AET 100 + Cis           | −1.90 ± 0.42†              | 9.23 ± 0.2*                     |
| AET 200 + Cis           | −1.80 ± 0.30*              | 9.03 ± 0.28*                    |
| AET 400 + Cis           | −2.14 ± 0.40**             | 10.01 ± 0.61**                  |

Values are expressed as mean ± SEM, n = 4. "P ≤ 0.01 vs normal control, *P ≤ 0.05 vs normal control, †P ≤ 0.05 vs cisplatin, ns = non-significant vs normal control, NS = non significant vs cisplatin. AET = Amla ethanolic extract, Cis = Cisplatin.
physiological levels of SOD were maintained in all the groups other than cisplatin treated group.

### 3.3.3. Effect of leaf extract on glutathione peroxidase (GPx) activity

The GPx activity was significantly elevated to the normal levels by all the above doses of leaf extract, however, a more pronounced effect ($p \leq 0.001$) was noticed at the dose 200 mg/kg BW when compared to cisplatin treated group. Also, the groups receiving leaf extracts alone did not show any significant difference in GPx activity when compared to the normal control group (Table 3; Fig. 2C).

### 3.3.4. Effect of leaf extract on glutathione reductase (GR) activity

All the above doses of leaf extract were able to significantly ($p \leq 0.05$) elevate the GR activity almost equivalent to the control group when compared with cisplatin treated group. Also, the rats receiving only leaf extracts did not show any significant difference in GR activity when compared to normal control group (Table 3; Fig. 2D).

### 3.3.5. Effect of leaf extract on renal MDA level

Oral administration of 100 mg/kg, 200 mg/kg and 400 mg/kg doses of leaf extract resulted in a significant ($p \leq 0.05$) reduction in renal tissue MDA levels when compared to cisplatin treated group. Also, the groups receiving leaf extracts only did not show any significant difference in MDA level when compared to normal control group (Table 4; Fig. 3).

### 3.4. Histopathological study

H&E staining of kidney sections showed severe damage in cisplatin treated group (Fig. 4C), there is widespread necrosis, cellular swelling, sloughing of Bowman’s capsule and degeneration of glomerulus, also in certain areas hemorrhage and polymorphic nuclei in renal tubular cells was observed, another noticeable feature is the dilated proximal convoluted tubule and distal convoluted tubule with sloughed off epithelium cells. In kidney sections of normal control, vehicle control and in groups receiving various dose of leaf extract (Fig. 4A, B, D, F, H) no pathological changes were observed. However, the groups receiving both cisplatin and various doses of leaf extract (Fig. 4E, G, I) showed slight necrosis and cellular swelling in renal tubules, sloughing of Bowman’s capsule and degeneration of glomerulus was considerably less when compared with cisplatin treated group. Among all the three groups receiving different doses of the leaf extract, tubular damage was less evident in group receiving 100 mg/kg and 200 mg/kg BW of leaf extract as compared 400 mg/kg BW suggesting the effect is dose dependent.

### 3.5. Effect of cisplatin and leaf extract on blood cell morphology

The effect of cisplatin on the morphology of blood cells of rats is shown in Fig. 5. Results suggest that the blood cells of normal control and vehicle control were similar in appearance, ellipsoidal in shape with intact cell wall. Contrary to this the blood cells of cisplatin treated rats appeared irregular in shape. The other visible effect that was evident in cisplatin treated group was lysis of red blood cells with disintegration of cell membrane and clumping of the nuclear material. Comparison of blood cells of the rats receiving leaf extract and the control rats showed a normal morphology with no symptoms of toxicity which is in contrast to the cisplatin treated group.

### 4. Discussion

Despite of dose and duration dependent renal toxicity induced by cisplatin, it is still widely used in various cancer therapies. Among all the described pathways involved in nephrotoxicity, oxidative stress is most prominent. Hence, the agents which can guard against the

---

### Table 3

| Groups                      | Cytocatalase (U/mg protein) | SOD (% NBT reduction/min) | GPx (U/g tissue) | GR (pmole/min/mg protein) |
|-----------------------------|----------------------------|---------------------------|------------------|--------------------------|
| Normal Control              | 31.41 ± 0.06               | 36.45 ± 1.36              | 51.28 ± 0.89     | 11.00 ± 0.21             |
| Vehicle Control             | 35.72 ± 1.65**             | 35.18 ± 3.31**            | 42.65 ± 3.80**   | 11.79 ± 0.27**           |
| Cisplatin                   | 22.45 ± 0.47**             | 16.13 ± 1.16**            | 12.83 ± 1.37**   | 0.90 ± 0.000**           |
| AET 100 mg/kg              | 27.84 ± 0.79**             | 36.46 ± 0.64**            | 56.69 ± 1.16**   | 10.04 ± 0.000**          |
| AET 200 mg/kg              | 28.22 ± 0.99**             | 41.88 ± 0.92**            | 57.04 ± 3.07**   | 10.04 ± 0.000**          |
| AET 400 mg/kg              | 28.75 ± 1.27**             | 37.82 ± 0.50**            | 52.73 ± 2.07**   | 12.41 ± 0.000**          |
| AET 100 + Cis              | 31.00 ± 0.98**             | 31.27 ± 1.21**            | 66.11 ± 1.45**   | 9.97 ± 0.54**            |
| AET 200 + Cis              | 30.21 ± 1.39**             | 32.35 ± 2.85**            | 72.63 ± 0.50**   | 11.11 ± 0.58**           |
| AET 400 + Cis              | 26.25 ± 0.78**             | 25.60 ± 1.47**            | 63.03 ± 2.25**   | 09.49 ± 0.29**           |

Values are expressed as mean ± SEM, $n = 4$. *$p \leq 0.01$ vs normal control, **$p \leq 0.001$ vs cisplatin, ***$p \leq 0.001$ vs cisplatin, # $p \leq 0.05$ vs cisplatin, ns = non significant vs normal control, NS = non significant vs cisplatin, AET = Amla ethanolic extract, Cis = Cisplatin.
oxidative stress in renal tissues with its exogenous antioxidants and additional properties like anti-inflammatory and cytoprotective should be used in combination with the chemotherapy drugs to reduce nephrotoxic and harmful effects of drugs like cisplatin. Although many agents have been reported to protect renal tissues via decreasing oxidative stress, still none of them has proved to be clinically effective [11].

In the present study, we have attempted to investigate the effect of hydro-ethanolic extracts of *E. officinalis* (Common name: Indian Gooseberry or Amla) leaf on CP-induced nephrotoxicity in rats. Research from other labs has confirmed that Phytoconstituents of Amla leaves have antioxidative, anti-carcinogenic, antidiabetic and anti-inflammatory potential [19–22] and play a significant role in ameliorating the oxidative stress [23]. Based on the above phytochemical and pharmacological properties, we investigated the protective role of the crude hydro-ethanolic extract of *E. officinalis* leaves in cisplatin induced nephrotoxicity.

For this study we have used 12 mg/kg BW [31] dose of cisplatin which is slightly less than higher dose of cisplatin (16 mg/kg BW)
Fig. 4. Histopathological Study: (A) Normal control (B) Vehicle control (C) Cisplatin (D) AET 100 mg/kg (E) AET 100 mg/kg + CIS (F) AET 200 mg/kg (G) AET 200 mg/kg + CIS (H) AET 400 mg/kg (I) AET 400 mg/kg + CIS. AET = Amla ethanolic extract, CIS = Cisplatin, BC = Bowman’s capsule, G = Glomerulus, PT = Proximal Tubule, DT = Distal Tubule.

Fig. 5. Study of blood cell morphology: (A) Normal control (B) Vehicle control (C) Cisplatin (D) AET 100 mg/kg (E) AET 100 mg/kg + CIS (F) AET 200 mg/kg (G) AET 200 mg/kg + CIS (H) AET 400 mg/kg (I) AET 400 mg/kg + CIS. AET = Amla ethanolic extract, CIS = Cisplatin.
which corresponds to the dose used in clinical practice [32]. It is reported that Rats showed signs of nephrotoxicity at a dose > 5 mg/kg BW of cisplatin [33,34]. Evaluation of Nephroprotective activity by various agents can be done with higher doses of cisplatin [35]. Higher dose of cisplatin also induces other toxic effects and provides a better chance to evaluate the potential of the supplemental compound for its efficiency in regulating the toxic effects.

The results obtained from the present study clearly suggest that the hydro-ethanolic fractions of E. officinalis leaves supplementation suppressed the Cisplatin-induced damage to the kidney which is reflected by normal values of BUN and creatinine markers. The level of serum creatinine and BUN was enhanced significantly in cisplatin treated group compared to the normal groups. Increased creatinine and urea levels are the markers of renal dysfunction and enhanced in those taking nephrotoxic medications [36–39]. Treatment with different doses of (100 mg/kg, 200 mg/kg, and 400 mg/kg BW) E. officinalis leaf extract significantly reduced the serum creatinine and BUN to normal levels (Table 2, Fig. 1). These results are similar to the study in which E. officinalis dried fruit extract was used with cisplatin [24]. Increased creatinine in cisplatin control group may be due to up regulation of Guanidinoacetate methyltransferase (GAMT) [40,41].

Also a single dose of cisplatin resulted in significant loss in body weight and increase in relative kidney weight. In our results we reported that the treatment group receiving E. officinalis leave extract 100 mg/kg and 200 mg/kg BW showed a significant increase in body weight and decrease in relative kidney weight, however higher dose did not cause any significant change in kidney/body weight (Table 1). This results are in accordance with previous reports [42,43]. This weight loss in cisplatin treated rats was may be due to gastrointestinal toxicity and reduced ingestion of food.

We also analyzed various antioxidant enzyme levels which get affected by severe nephrotoxicity caused by the administration of cisplatin. Our data suggests that a single dose of cisplatin resulted in a significant decrease in activity of different antioxidative enzymes (SOD, CAT, GPx, and GR) in cisplatin group compared to normal rats, accompanied by an increase in lipid peroxidation as evidenced by significant increase in MDA level in cisplatin group. This results supports observation of previous studies that provided evidence that cisplatin mediated nephrotoxicity mainly involve Reactive Oxygen Species (ROS) generation and decrease in activities of enzymatic and non-enzymatic antioxidative defense [36,43,44]. The oxidative damage induced by cisplatin has been associated with damage to mitochondrial respiratory chain, which causes an increase in the generation of ROS such as superoxide anions (O$_2^-$) and H$_2$O$_2$ and subsequent depletion of non-enzymatic (GSH and NADPH) and the enzymatic antioxidant defense system (SOD, CAT, GPx, and GR) in rat kidneys. Superoxide anions might originate hydroxyl radicals by partial reduction catalyzed by transition metals, mainly iron. Hydroxyl radicals are very strong oxidants that react with any component of cell like lipids, proteins and DNA, leading to loss in cell integrity, enzyme function and genomic stability [4]. Administration of E. officinalis leaf extract significantly enhanced the activities of above enzymes thereby, ameliorating the toxic effect of cisplatin on renal cells. The lower doses of E. officinalis leave extract (100 mg/kg and 200 mg/kg) appear to be protective and elevated the enzymatic activity to counter the nephrotoxic effect of cisplatin. However, higher, doses of 400 mg/kg of leaf extract were not effective in up regulating the Catalase activity.

It is also evident from the findings that the leaf extract used in this study more significantly acted on the activity of GPx compared to other enzymes. Some reports suggest that CAT activity was more vulnerable than SOD activity or GPx activity in cisplatin induced nephrotoxicity [45]. The decrease in activity of SOD and CAT causes increased lipid peroxidation in cisplatin treated group as evidenced by an increase in concentration of the renal MDA level, which remained low in groups that received different doses of leaf extract (100 mg/kg, 200 mg/kg and 400 mg/kg BW) (Tables 3 and 4, Figs. 2 and 3). We hypothesize that the protective role of E. officinalis leaf extract supplementation may be due to reduction in oxidative stress via enhancing activities of various enzymatic antioxidants. The results reported here are similar to the findings of other studies [31,46–48].

Histopathological examination revealed intact glomerulus and normal renal tubules with no pathological changes in normal control, vehicle control groups and groups receiving leaf extracts (Fig. 4A, B, D, F, H). However, severe damage in glomerulus and renal tubules was noted in cisplatin treated groups, supporting the findings of previous studies [1,36,46,49]. Treatment with different doses of E. officinalis leaf extract for 13 days not completely reduces the damage as evidenced by many degenerating tubules but the damage was significantly less when compared with the cisplatin treated group (Fig. 4E, G, I). Among all the three doses the damage was least in group receiving 100 mg/kg and 200 mg/kg leaf extract supporting the above biochemical observations.

One common side effect of cisplatin and other platinum compounds is anemia, especially after repeated infusions. The primary cause may be due to myelosuppression resulting in lower count of red cell precursors. Some authors reported hemolytic anemia caused by an anti-globulin antibody directed against red cell membrane bound cisplatin [50]. Kutwin et al. [51] reported structural damage of chicken red blood cells exposed to cisplatin, causing deformity and swelling of red blood cells as a result of membrane damage. However, other studies have not shown any harmful effect on human red blood cell morphology. In the present study, a single dose of 12 mg/kg BW of cisplatin resulted in morphological changes and hemolysis of red blood cells when compared to the control groups (Fig. 5). Treatment with different doses of E. officinalis leaf extract for 13 days prevents cisplatin induced RBC damage almost to the normal, thereby reducing the toxic manifestation of cisplatin on RBCs.

5. Conclusion

A single dose of cisplatin (12 mg/kg BW) leads to significant renal damage as evidenced by oxidative stress and histological damage. E. officinalis hydro-ethanolic leaf extract significantly reduces the oxidative stress. Our results also suggest that the hydro-ethanolic leaf extract of E. officinalis contains phytochemicals, which may be protecting nephrotoxicity induced by cisplatin by enhancing the activities of enzymatic and non-enzymatic antioxidative defense system. Further studies are warranted to identify the nature of the actual compounds responsible for nephroprotection present in the E. officinalis leaf extract and the possible mechanisms by which they work to rescue the oxidative damage to the kidney cells.

Conflict of interest

The authors declare that there are no conflicts of interest.

Acknowledgements

Authors (R.P) acknowledge the funding from Rajiv Gandhi National Fellowship vide ref. no. RGNF-2015-17-SC-CHH-20147. Authors are also thankful to Prof. Amit Roy (Principal) and Dr. Trilochan Satpathy (Associate Professor) Columbia Institute of Pharmacy, Raipur, C.G., for providing animal study facilities.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.toxrep.2018.01.008.

References

[1] S. Uppuluri, S.L. Ali, T. Nirmala, M. Shanthi, B. Sipay, K.B. Uppuluri, Nephroprotector activity of hydro alcoholic extract of Tinospora cordifolia roots on
cisplatin induced nephrotoxicity in rats. Drug. Invest. Today 5 (4) (2013) 281–287.
[2] N. Pabla, Z. Dong, Cisplatin nephrotoxicity: mechanisms and renoprotective strategies, Kidney Int. 73 (9) (2008) 994–1007.
[3] J. Rejebi, F.H.M. Lohnan, Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm. World Sci. 7 (7) (1985) 173–180.
[4] N.A.G. dos Santos, M.A.C. Rodrigues, N.M. Martins, A.C. dos Santos, Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch. Toxicol. 86 (8) (2012) 1233–1256.
[5] A.M. Fleroa, D. Busselberg, Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects, Cancer 3 (1) (2011) 1351–1371.
[6] H.S. Lee, B.K. Kim, Y. Nam, U.D. Sohn, E.S. Park, S.A. Hong, J.H. Lee, Y.H. Chung, J.H. Jeong, Protective role of phosphatidylcholine against cisplatin induced renal toxicity and oxidative stress in rats. Chem. Pharmacol. 58 (2013) 388–392.
[7] C. Mamoulakis, K. Tsarouchas, I. Fragkiadoulaki, I. Heretis, M.I. Wilks, D.A. Spandolis, T. Christou, A. Tsatsakis, Contrast-induced nephropathy: basic concepts, pathophysiological implications and prevention strategies, Pharmacol. Ther. 180 (2017) 99–112.
[8] A. Longcharr, S.B. Prasad, Biochemical changes associated with ascorbic acid-, cisplatin combination therapeutic efficacy and protective effect on cisplatin-induced toxicity in tumor-bearing mice. Toxicol. Rep. 2 (2015) 489–503.
[9] G. Rosic, I. Srejovic, V. Zivkovic, D. Selakovic, J. Joksimovic, V. Jakovljevic, The effects of N-acetylcysteine on cisplatin-induced cardiotoxicity on isolated rat hearts after short-term global ischemia. Toxicol. Rep. 2 (2015) 996–1006.
[10] A.Y. Nazar, Protective effect of aged garlic extract against the oxidative stress induced by cisplatin on blood cells parameters and hepatic antioxidant enzymes in rats. Toxicol. Rep. 1 (2014) 682–691.
[11] R.P. Miller, R.K. Tadagavadi, G. Ramesh, W.B. Reeves, Mechanisms of cisplatin treatment and prevention of cancer, Eur. J. Cancer Prev. 20 (3) (2011) 225–238.
[12] M.S. Baliga, J.J. Dsouza, Amla (Phyllanthus emblica Gaertn. Leaves extract in streptozotocin-induced type-2 diabetes mellitus (T2DM) rats. J. Ethnopharmacol. 142 (1) (2012) 65–71.
[13] S. Masyayu, Y. Hiroshi, A simplified assay method of superoxide dismutase activity for clinical use. Clin. Chim. Acta 92 (3) (1979) 337–342.
[14] D.E. Paglia, W.N. Valentine, Studies on the quantitative and qualitative characterization of erythrocyte glutathione Peroxidase, Transl. Res. 70 (1) (1967) 158–169.
[15] G. Cohen, D. Dembic, J. Marcus, Measurement of catalase activity in tissue extracts, Anal. Biochem. 34 (1) (1979) 30–38.